Testosterone News and Research

Latest Testosterone News and Research

Acupuncture and exercise help women with PCOS

Acupuncture and physical exercise improve hormone levels and menstrual bleeding pattern in women with polycystic ovary syndrome (PCOS), reveals research from the University of Gothenburg, Sweden.

7 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Longer life with osteoporosis therapy: Study

In a new breakthrough, Australian scientists have identified the “remarkable” life-extending properties of an osteoporosis treatment. The research is published in the Journal of Endocrinology and Metabolism on Thursday.

3 Feb 2011

Nutritional supplements and seniors: New study

The University of Adelaide will be embarking on a new study that will look into the benefits of providing nutritional supplements and small doses of hormones to elderly people.

2 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Lipocine Inc. announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T). These applications cover Lipocine's novel oral testosterone product (LPCN 1021) being developed to overcome the issues with currently marketed topical, parenteral, and transdermal testosterone products.

28 Jan 2011

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer.

25 Jan 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

A study from the University of Gothenburg, shows that women with polycystic ovary syndrome (PCOS) have aberrations in their adipose tissue.

17 Jan 2011

Researchers discover molecular mechanism behind coffee's protective effect

Coffee, that morning elixir, may give us an early jump-start to the day, but numerous studies have shown that it also may be protective against type 2 diabetes. Yet no one has really understood why.

14 Jan 2011

BPA more harmful to women with hormonal and fertility imbalances

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), found higher Bisphenol A (BPA) levels in women with polycystic ovary syndrome (PCOS) compared to controls. Furthermore, researchers found a statistically significant positive association between male sex hormones and BPA in these women suggesting a potential role of BPA in ovarian dysfunction.

13 Jan 2011

Fertile women gravitate toward males with masculine facial features

When their romantic partners are not quintessentially masculine, women in their fertile phase are more likely to fantasize about masculine-looking men than are women paired with George Clooney types.

11 Jan 2011

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

BioSante Pharmaceuticals, Inc., a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).

11 Jan 2011

Women’s tears dampen men’s libido: Study

New research confirms an age old fear – men are truly turned off if the woman sheds tears. The researchers found that men who smelled the tears of weeping women produced less testosterone and found female faces less arousing.

10 Jan 2011

Sniffing women's tears reduces sexual arousal in men

Emotional crying is a universal, uniquely human behavior. When we cry, we clearly send all sorts of emotional signals. In a paper published online today in Science Express, scientists at the Weizmann Institute have demonstrated that some of these signals are chemically encoded in the tears themselves. Specifically, they found that merely sniffing a woman's tears - even when the crying woman is not present -- reduces sexual arousal in men.

7 Jan 2011

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.

3 Jan 2011

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010